Literature DB >> 27486286

Pros and Cons of Adding of Neoadjuvant Chemotherapy to Standard Concurrent Chemoradiotherapy in Cervical Cancer: A Regional Cancer Center Experience.

Satya Narayan1, Neeti Sharma2, Akhil Kapoor3, Rajani Sharma4, Narendra Kumar5, Mukesh Singhal3, Ramesh Purohit3, Shankar Lal Jakhar2, Surendra Beniwal6, Harvindra Singh Kumar2, Ajay Sharma2.   

Abstract

BACKGROUND: The present study summarizes the results of treatment in the form of disease-free survival and overall survival in bulky stage IB2 and locally advanced (stages II-IVA) squamous cell carcinoma of the uterine cervix. The treatment has been given in the form of NACT followed by CCRT in one arm and CCRT in the other arm.
MATERIALS AND METHODS: This retrospective study analyzed 713 cervical cancer patients who were treated at our center during 2007 and 2008; out of 713 patients, data of 612 patients have been compared. The patients' data were analyzed retrospectively. Patients had undergone PF 28.6 %, TPF 21.5 %, and only CCRT 49.9 %. Majority of patients were in the age group 41-50 years, while stage wise, mainly stage IIIb and IIb. Disease-free survival was observed on the basis of stage and NACT. The survival analyses were performed using the Kaplan-Meier method. All statistical calculations were done with SPSS Statistics version 20.0.
RESULTS: For cancer cervix NACT versus CCRT, the DFS rate was at 5 years (58.3 vs. 41.8 % p = 0.001). NACT followed by CCRT demonstrated significantly superior DFS as compared to definitive CCRT, respectively, TPF (hazard ratio (HR) = 0.248, 95 % confidence interval (CI) 0.123-0.500; p < 0.001), PF (HR = 0.445, 95 % CI 0.266-0.722; p = 0.002). The results of univariate stage, age, and multivariate study show that stage hemoglobin level, interval between external-intracavitary radiation, and type of neoadjuvant chemotherapy were the factors affected survival cervical patients treated with radiation. The grade 3/4 hematologic toxicities were more in the NACT group than CCRT (p < 0.001) while the non-hematological toxicity was not significant; the TPF group experienced more toxicity than PF (p = 0.029). This treatment regimen is feasible as evidenced by the acceptable toxicity of NACT and by the high compliance to radiotherapy. The grade 3/4 hematologic toxicities were more in NACT groups than CCRT (p < 0.001); the TPF group experienced more toxicity than PF (p = 0.029).
CONCLUSION: TPF/PF as NACT is feasible and produces impressive responses in cancer cervix.

Entities:  

Keywords:  Cervical cancer; Disease-free survival; Hematological; Neoadjuvant chemotherapy

Year:  2015        PMID: 27486286      PMCID: PMC4958073          DOI: 10.1007/s13224-015-0698-5

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  6 in total

1.  Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results.

Authors:  J E Sardi; A Giaroli; C Sananes; M Ferreira; A Soderini; A Bermudez; L Snaidas; S Vighi; N Gomez Rueda; G di Paola
Journal:  Gynecol Oncol       Date:  1997-10       Impact factor: 5.482

Review 2.  Worldwide burden of gynaecological cancer: the size of the problem.

Authors:  R Sankaranarayanan; J Ferlay
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2005-12-13       Impact factor: 5.237

3.  Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer--a meta-analysis.

Authors:  H Lukka; H Hirte; A Fyles; G Thomas; L Elit; M Johnston; M Fung Kee Fung; G Browman
Journal:  Clin Oncol (R Coll Radiol)       Date:  2002-06       Impact factor: 4.126

Review 4.  Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomised trials.

Authors: 
Journal:  Eur J Cancer       Date:  2003-11       Impact factor: 9.162

5.  Experience in stage IB2 cervical cancer and review of treatment.

Authors:  Taner Turan; Burcu Aykan Yıldırım; Gökhan Tulunay; Nurettin Boran; Ferah Yıldız; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2010-03-01

6.  A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer.

Authors:  M McCormack; L Kadalayil; A Hackshaw; M A Hall-Craggs; R P Symonds; V Warwick; H Simonds; I Fernando; M Hammond; L James; A Feeney; J A Ledermann
Journal:  Br J Cancer       Date:  2013-05-21       Impact factor: 7.640

  6 in total
  8 in total

1.  Molecular markers of DNA damage and repair in cervical cancer patients treated with cisplatin neoadjuvant chemotherapy: an exploratory study.

Authors:  Nilda E Real; Gisela N Castro; F Darío Cuello-Carrión; Claudia Perinetti; Hanna Röhrich; Niubys Cayado-Gutiérrez; Martin E Guerrero-Gimenez; Daniel R Ciocca
Journal:  Cell Stress Chaperones       Date:  2017-06-12       Impact factor: 3.667

Review 2.  Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy Alone in Locally Advanced Carcinoma of Cervix.

Authors:  Aradhna Tripathi; Shyamji Rawat
Journal:  J Obstet Gynaecol India       Date:  2019-07-13

3.  Hedychium coronarium extract arrests cell cycle progression, induces apoptosis, and impairs migration and invasion in HeLa cervical cancer cells.

Authors:  Asit Ray; Sudipta Jena; Biswabhusan Dash; Ambika Sahoo; Basudeba Kar; Jeetendranath Patnaik; Pratap Chandra Panda; Sanghamitra Nayak; Namita Mahapatra
Journal:  Cancer Manag Res       Date:  2019-01-03       Impact factor: 3.989

4.  Neoadjuvant chemotherapy does not improve the prognosis and lymph node metastasis rate of locally advanced cervical squamous cell carcinoma: A retrospective cohort study in China.

Authors:  Wenxing Yan; Lihui Si; Yaming Ding; Shuang Qiu; Qi Zhang; Linlin Liu
Journal:  Medicine (Baltimore)       Date:  2019-09       Impact factor: 1.817

5.  Comparison of outcomes and side effects for neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation vs. chemoradiation alone in stage IIB-IVA cervical cancer: study protocol for a randomized controlled trial.

Authors:  Jing Li; Hua Liu; Ya Li; Jian Li; Lifei Shen; Wenqing Long; Chenmin Yang; Haoping Xu; Wenqi Xi; Rong Cai; Weiwei Feng
Journal:  Trials       Date:  2022-01-10       Impact factor: 2.279

6.  MAP4K4 mediates the SOX6-induced autophagy and reduces the chemosensitivity of cervical cancer.

Authors:  Hongxin Huang; Qin Han; Han Zheng; Mingchen Liu; Shu Shi; Ting Zhang; Xingwen Yang; Zhongqing Li; Qiang Xu; Hongyan Guo; Fengmin Lu; Jie Wang
Journal:  Cell Death Dis       Date:  2021-12-20       Impact factor: 8.469

7.  A Comparison of Different Schemes of Neoadjuvant Chemotherapy Followed by Concurrent Chemotherapy and Radiotherapy for Locally Advanced Cervical Cancer: A Retrospective Study.

Authors:  Xue Tian; Feiyue Yang; Fenghu Li; Li Ran; Jianying Chang; Jiehui Li; Wei Hong; Lang Shan; Yanjun Du; Lili Hu; Fan Mei; Mingyuan He; Yongxia Li; Heran Wang; Kai Zuo; Bo Zhou; Shuying Chen; Wanli Mao
Journal:  Cancer Manag Res       Date:  2021-11-03       Impact factor: 3.989

8.  Outcome evaluation of neoadjuvant chemotherapy in patients with stage IB2 or IIA cervical cancer: a retrospective comparative study.

Authors:  Wenxing Yan; Shuang Qiu; Lihui Si; Yaming Ding; Qi Zhang; Linlin Liu
Journal:  Transl Cancer Res       Date:  2020-03       Impact factor: 1.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.